0001209191-17-063672.txt : 20171204
0001209191-17-063672.hdr.sgml : 20171204
20171204193914
ACCESSION NUMBER: 0001209191-17-063672
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171130
FILED AS OF DATE: 20171204
DATE AS OF CHANGE: 20171204
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Herberts Curt A. III
CENTRAL INDEX KEY: 0001691262
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30171
FILM NUMBER: 171238398
MAIL ADDRESS:
STREET 1: 501 CANAL BLVD.
STREET 2: POINT RICHMOND TECH CENTER
CITY: RICHMOND
STATE: CA
ZIP: 94804
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC
CENTRAL INDEX KEY: 0001001233
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 680359556
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 501 CANAL BLVD
STREET 2: POINT RICHMOND TECH CNTR.
CITY: RICHMOND
STATE: CA
ZIP: 94804
BUSINESS PHONE: 5109706000
MAIL ADDRESS:
STREET 1: 501 CANAL BLVD
STREET 2: POINT RICHMOND TECH CNTR.
CITY: RICHMOND
STATE: CA
ZIP: 94804
FORMER COMPANY:
FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC
DATE OF NAME CHANGE: 20000208
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-11-30
0
0001001233
SANGAMO THERAPEUTICS, INC
SGMO
0001691262
Herberts Curt A. III
C/O SANGAMO THERAPEUTICS, INC.
POINT RICHMOND TECH CTR, 501 CANAL BLVD.
RICHMOND
CA
94804
0
1
0
0
Sr.VP & Chief Business Officer
Common Stock
2017-11-30
4
M
0
13433
9.41
A
31266
D
Common Stock
2017-11-30
4
S
0
13433
16.00
D
17833
D
Common Stock
2017-12-01
4
M
0
781
9.41
A
18614
D
Common Stock
2017-12-01
4
M
0
416
8.87
A
19030
D
Common Stock
2017-12-01
4
S
0
3197
16.70
D
15833
D
Stock Option (Right to Buy)
9.41
2017-11-30
4
M
0
13433
0.00
D
2025-12-07
Common Stock
13433
20313
D
Stock Option (Right to Buy)
9.41
2017-12-01
4
M
0
781
0.00
D
2025-12-07
Common Stock
781
19532
D
Stock Option (Right to Buy)
8.87
2017-12-01
4
M
0
416
0.00
D
2025-07-26
Common Stock
416
4168
D
Includes 2,000 shares acquired by the Reporting Person on October 31, 2017 under the Issuer's Employee Stock Purchase Plan.
All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2017.
The shares were sold at prices ranging from $16.25 to $17.175 The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the December 8, 2015 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the July 27, 2015 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
/s/ Denise Winn, Attorney-in-Fact
2017-12-04